Paroxetine Discontinuation Syndrome: Evidence‑Based Risks, Clinical Features, Management, and Prevention

Risk Factors

• Paroxetine carries the highest risk of discontinuation syndrome among selective serotonin‑reuptake inhibitors (SSRIs) because of its short elimination half‑life and absence of active metabolites (American Academy of Child and Adolescent Psychiatry evidence) [1][2]3.

Clinical Presentation

• The syndrome commonly manifests with a broad array of physical and psychological symptoms, including dizziness, fatigue, lethargy, general malaise, muscle aches, chills, headache, nausea, vomiting, diarrhea, insomnia, imbalance, vertigo, sensory disturbances, paresthesias, anxiety, irritability, and agitation (American Academy of Child and Adolescent Psychiatry) [1][2]3.

Management Decisions for Prolonged Symptoms

• Re‑initiation of paroxetine should be contemplated when discontinuation symptoms produce significant distress or impair daily functioning (Mayo Clinic Proceedings) [4][5].

Prevention and Tapering Recommendations

• The American Academy of Child and Adolescent Psychiatry advises a gradual dose reduction rather than abrupt cessation of paroxetine; if intolerable symptoms emerge, the previously prescribed dose may be reinstated temporarily, followed by a slower taper (multiple guideline statements) [6][1][2][3][7][8].